SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction

By sjmartinez • October 29, 2023

Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang EH, Ky B, Lenihan D, Nohria A, Dani SS, Ganatra S. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction. JACC Heart Fail. 2023 Oct 12:S2213-1779(23)00596-6. doi: 10.1016/j.jchf.2023.08.026. Epub ahead of print. PMID: 37897456.

Tags: antineoplastic therapy, cardiomyopathy, Digestive Diseases, Outcomes, Publications, SGLT2 inhibitors

The PTPN2 rs1893217 IBD risk allele increases susceptibility to AIEC invasion by a JAK-STAT-CEACAM6 axis

Chatterjee P, Canale V, King SJ, Shawki A, Lei H, Santos AN, Haddad M, Gries C, McGovern DPB, Borneman J, McCole DF. The PTPN2 rs1893217 IBD risk[...]

Distal esophageal acid exposure and poor esophageal clearance correlate with probability of progression in Barrett’s esophagus as determined by the tissue systems pathology test

Eriksson SE, Kolb JM, Nguyen J, Sarici IS, Zheng P, Ayazi S. Distal esophageal acid exposure and poor esophageal clearance correlate with probability of progression[...]

Impact of Short Duration FODMAP Restriction on Breath Gases and Gastrointestinal Symptoms

Pathipati MP, Shortt A, Shortt C, McBride B, O'Rourke L, Burke R, Chey WD, Chang L, Staller K. Impact of Short Duration FODMAP Restriction on[...]